Novartis OTC Facility Improves Regulatory Report Card
This article was originally published in The Tan Sheet
CEO Joe Jimenez says FDA officials did not make form 483 observations following a week-long inspection of the firm’s Lincoln, Neb., plant. Consumer product sales increased 11% in the third quarter as Novartis returned some recalled OTC brands to U.S. stores.
You may also be interested in...
Novartis CEO Joe Jimenez made clear the firm is considering divesting its consumer product, animal health and vaccines and diagnostics business, Sanford and Bernstein analysts say. “It seems that Novartis will be making final decisions with these units fairly soon,” they say.
So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.
Perrigo "walked away a little bit" from "a model that worked beautifully," says CEO Murray Kessler at investor conference, "In essence, all we've done over the last year is to put back in place the model that worked so well."